| Market Cap | 3.17M | P/E | - | EPS this Y | 64.20% | Ern Qtrly Grth | - |
| Income | -12.54M | Forward P/E | -0.20 | EPS next Y | -403.80% | 50D Avg Chg | -30.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -49.00% |
| Dividend | N/A | Price/Book | 0.42 | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | 3.00 | Quick Ratio | 4.54 | Shares Outstanding | 4.78M | 52W Low Chg | 15.00% |
| Insider Own | 6.08% | ROA | -75.90% | Shares Float | 3.59M | Beta | 1.00 |
| Inst Own | 5.50% | ROE | -160.07% | Shares Shorted/Prior | 115.61K/14.39K | Price | 0.95 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 111,506 | Target Price | 3.25 |
| Oper. Margin | - | Earnings Date | May 9 | Volume | 35,692 | Change | 7.12% |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Burleson Tess | Director Director | Jun 07 | Buy | 0.18 | 27,700 | 4,986 | 32,050 | 06/08/22 |
| Lieber Jonathan I | Director Director | Jun 07 | Buy | 0.1871 | 37,500 | 7,016 | 37,500 | 06/08/22 |
| HANISH ARNOLD C | Director Director | Jun 03 | Buy | 0.184 | 28,000 | 5,152 | 46,350 | 06/06/22 |
| HANISH ARNOLD C | Director Director | Aug 21 | Buy | 0.98 | 4,000 | 3,920 | 11,350 | 06/06/22 |
| HANISH ARNOLD C | Director Director | Feb 11 | Buy | 1.15 | 4,350 | 5,002 | 7,350 | 06/06/22 |
| HANISH ARNOLD C | Director Director | Nov 25 | Buy | 3.59 | 3,000 | 10,770 | 3,000 | 06/06/22 |
| Arthur David J. | Chief Executive Offi.. Chief Executive Officer | May 26 | Buy | 0.18 | 43,900 | 7,902 | 303,574 | 05/31/22 |
| Rosenblum Mark J | Exec VP Finance, CFO Exec VP Finance, CFO | May 31 | Buy | 0.18 | 28,000 | 5,040 | 148,319 | 05/31/22 |
| Rosenblum Mark J | Exec VP Finance, CFO Exec VP Finance, CFO | Mar 03 | Buy | 0.391 | 76,246 | 29,812 | 110,319 | 03/09/22 |
| Arthur David J. | Chief Executive Offi.. Chief Executive Officer | Mar 03 | Buy | 0.391 | 139,488 | 54,540 | 249,674 | 03/09/22 |